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Abstract
Background: We report changes of choroidal structure determined by binarization of enhanced depth imaging
optical coherence tomographic (EDI-OCT) images after treatment for primary intraocular lymphoma (PIOL).
Methods: Five eyes of four patients with PIOL were examined by EDI-OCT before and 6 months after intravitreal
methotrexate injections. In addition, 15 eyes of 15 normal individuals controlled by age and refractive error were
examined by EDI-OCT. Binarization of the EDI-OCT images was performed using publicly accessible software (ImageJ).
The examined area of the subfoveal choroid was 1,500 μm wide, and the dark areas that represented the luminal areas
were traced by the Niblack method. Wilcoxon signed rank test was used to determine the significance of changes in
the subfoveal choroidal thickness, interstitial area, and luminal area. Mann–Whitney U test was used to compare the
parameters in the eyes with pretreatment PIOL and normal control eyes.
Results: The subfoveal choroidal thickness was significantly decreased after treatment (P = 0.0431). In the binarized
images, the interstitial area was significantly decreased after treatment (P = 0.0431), while the luminal area was not
significantly changed (P = 0.8927). After delayed onset of PIOL, increased interstitial area, thickened choroid and
unchanged luminal area were observed in one eye. The interstitial area and choroidal thickness were significantly
increased in the eyes with pretreatment PIOL compared with the normal control eyes (P = 0.0207, P = 0.0495,
respectively), while the luminal area was not significantly different (P = 0.2752).
Conclusions: After treatment for PIOL, the EDI-OCT images showed a thinner choroid, and binarization of the EDI-OCT
images showed significantly decreased interstitial areas compared with the luminal areas. The binarized EDI-OCT
images can provide useful information on choroidal structure in eyes with PIOL, and combining these images with
intraocular interleukin levels or fundus autofluorescence images should provide valuable information for determining
the PIOL activity.
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Background
Intraocular lymphoma has two distinct forms: (1) arising
in the central nervous system (CNS) and/or the retina
and (2) arising outside the CNS with intraocular metas-
tasis [1, 2]. The latter is a non-primary CNS lymphoma
(non-PCNSL), and originates from systemic lymphomas
that metastasize via blood circulation to the uvea. The
former is called primary CNS lymphoma (PCNSL), and
has a much higher prevalence than non-PCNSL. Primary
intraocular lymphoma (PIOL) is a type of PCNSL. They
are generally classified as aggressive, diffuse, large B-cell
lymphomas. It has been reported that 15 % to 25 % of
PCNSL cases involved the eye, but PIOLs could be
present without CNS involvement [3, 4]. Patients with a
PIOL often have iritis, vitreous opacities, and retinal in-
filtrations, and are often misdiagnosed as having uveitis.
The prognosis of PIOL remains poor with a high ten-
dency to progress to PCNSL. Kimura et al. [5] reported
that the 5-year survival rate of PIOL was 61.1 %. There-
fore, it is important to diagnose PIOL promptly and to
accurately evaluate the effects of treatment.
Optical coherence tomographic (OCT) findings have
been recently reported to be helpful in determining the
retinal abnormalities in eyes with PIOL [6–10]. We have
reported retinal abnormalities on the OCT images in
three cases of PIOL before treatment [11]. We have also
reported that subfoveal choroidal thickness on the en-
hanced depth imaging OCT (EDI-OCT) images, grad-
ually decreased in one case during the treatment for
PIOL [12]. To the best of our knowledge, however, there
has been no report describing changes of the choroidal
structure in cases of PIOL after treatment. We also re-
cently reported that EDI-OCT images can be converted
to binary images, which can then be used to quantify the
luminal and interstitial areas of the choroid [13–15]. We
applied this technique to quantify the luminal and stromal
areas of the choroid in eyes with PIOL. The purpose of
this study was therefore to report changes of choroidal
structure determined by binarization of the EDI-OCT
images after treatment for PIOL.
Methods
Five eyes of four patients (three men and one woman)
with biopsy-diagnosed PIOL were examined by EDI-
OCT before and 6 months after intravitreal methotrex-
ate injections (IVMTXs). In addition, 15 eyes of 15 nor-
mal individuals controlled by age and refractive error
were examined by EDI-OCT. Patients were evaluated
and diagnosed in the Department of Ophthalmology of
Tokushima University Hospital. Approval was obtained
from the Institutional Review Board of Tokushima
University Hospital to perform this study, and the pa-
tients gave their written informed consent prior to
their inclusion in the study. The patients have provided
permission to publish clinical data of their case in this
study. Furthermore, the study adhered to the tenets of
the Declaration of Helsinki. All patients underwent diag-
nostic pars plana vitrectomy, and vitreous samples were
obtained during the vitrectomy. The diagnosis of PIOL
was made by the detection of malignant lymphocytes,
class IV or V, or an interleukin (IL)-10/IL-6 ratio > 1.0 in
the vitreous fluid. Two eyes were treated with oral pred-
nisolone before diagnostic vitrectomy, but EDI-OCT was
not performed before steroid therapy.
The patient demographics and clinical findings are
summarized in Table 1. The age of the patients ranged
from 59 to 77 years (mean, 65.0 years). The PIOL in two
patients was monocular, one patient had bilateral PIOL,
and another patient had PIOL in the right eye and a his-
tory of PIOL in the left eye. One patient had a history of
PCNSL. The cytological diagnoses were classes I, III,
and V in one eye each, and were not available in two
eyes. The IL-10/IL-6 ratio was > 1.0 in the vitreous of all
eyes. Vitreous opacities were observed in all eyes. Retinal
infiltrations and iritis were observed in two eyes each,
and retinitis was present in one eye. The number of
























1 59/M OD + N/A 825 45 18.3 Iritis,OCV 9 1.2 1.5
OS N/A 5080 89.5 56.8 Iritis,OCV 9 0.6 0.9
2 67/F OD - Class III 1870 1370 1.4 OCV, retinitis 8 0.9 0.9
3 77/M OS - Class I 696 35.6 19.6 OCV, retinal infiltration
(macula, periphery)
6 1.0 0.9
4 57/M OD - Died before
vitrectomy





OS Class V 3150 102 30.9 OCV, retinal infiltration
(macula)
9 0.9 1.2
BCVA best-corrected visual acuity, IL interleukin, IVMTX intravitreal injection of methtorexate, N/A not available, OCV vitreous opacity, OD right eye, OS left eye,
PCNSL primary central nervous system lymphoma, PIOL primary intraocular lymphoma
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IVMTXs during 6 months ranged from 6 to 9 times
(mean, 8.2 times). Before 6 months after the initial
IVMTX, the level of IL-10 in the aqueous humor be-
came undetectable in all eyes. The PIOL developed in a
delayed fashion in the healthy fellow eye of one patient
with unilateral PIOL, but this patient was dead of intra-
cranial lymphoma before diagnostic vitrectomy and ini-
tiation of IVMTX. The diagnosis of this delayed-onset
PIOL was made by the detection of an IL-10/IL-6
ratio > 1.0 in the aqueous fluid. The report of case 4 by
Egawa et al. [12] has already been published.
All patients had a standard ophthalmologic examin-
ation before and after the IVMTX. The examination
included measurement of best-corrected visual acuity,
applanation tonometry, slit lamp biomicroscopy, indirect
ophthalmoscopy, and color fundus photography (Fig. 1).
Spectral-domain OCT (SD-OCT) was performed with the
Heidelberg Spectralis (Heidelberg Engineering, Heidelberg,
Germany). The subfoveal choroidal thickness was manu-
ally measured using the caliper function, and the subfo-
veal choroidal thicknesses on vertical and horizontal
scans were averaged in each eye.
Binarization of a choroidal area in the EDI-OCT image
was done by a modified Niblack’s method as reported in
detail (Fig. 2) [14]. Briefly, an EDI-OCT image was ana-
lyzed by ImageJ software (ImageJ, version 1.47, NIH,
Bethesda, MD, USA). The examined area was 1,500 μm
wide in the subfoveal choroid, and extended vertically
from the retinal pigment epithelium (RPE) to the chor-
ioscleral border. This choroidal area was selected with
the ImageJ ROI Manager. Three choroidal vessels with
lumens larger than 100 μm were randomly selected by
the Oval Selection Tool on the ImageJ tool bar, and the
average reflectivity of these areas was determined. The
average brightness was set as the minimum value to
minimize noise in the OCT image. Then, the image
was converted to 8 bits and adjusted by the Niblack
Auto Local Threshold. The binarized image was con-
verted to the RGB image again, and the luminal area
was determined using the Threshold Tool. The light pixels
were defined as the interstitial areas, and the dark pixels
were defined as the luminal areas. After adding the data of
the distance of each pixel, the luminal and interstitial areas
were automatically calculated.
Wilcoxon signed rank test was used to determine the
significance of changes in the subfoveal choroidal thick-
ness, interstitial area and luminal area. Mann–Whitney
U test was used to compare the parameters in the 5
eyes with pretreatment PIOL and normal control eyes.
All analyses were done with the SPSS version 22.0
(IBM Japan, Ltd., Japan) and the StatView software
(Abacus; Abacus Concepts, Inc., Berkeley, California,
USA). A P value of < 0.05 was considered statistically
significant.
Results
Subfoveal choroidal thickness and areas in EDI-OCT
images before and after IVMTX are shown in Table 2.
The subfoveal choroidal thickness 6 months after the
initial IVMTX (182.7 ± 39.3 μm) was significantly de-
creased from that before IVMTX (215.6 ± 38.1 μm, P =
0.0431). In the binarized images, the interstitial area of
the 1500-μm-wide subfoveal choroid after treatment
(0.1088 ± 0.0167 mm2) was significantly decreased com-
pared with that before treatment (0.1240 ± 0.0200 mm2,
P = 0.0431), while the luminal area was not significantly
changed after IVMTX (0.1942 ± 0.0403 mm2 before treat-
ment, 0.2007 ± 0.0439 mm2 after treatment; P = 0.8927).
In addition, the pretreatment interstitial area was higher
in the affected eyes compared with the healthy fellow eyes
in cases 3 and 4 with unilateral PIOL. However, the inter-
stitial area was not higher in the affected eye compared
with the fellow eye with a history of PIOL in case 2. Not-
ably, the interstitial area and choroidal thickness were
increased after development of PIOL in the right eye of
case 4, while the luminal area was not changed.
Fig. 1 Fundus photograph in the left eye of case 4. a Before
treatment, fundus photograph after diagnostic vitrectomy shows
small yellowish lesions resembling drusen in the posterior fundus.
b Six months after the initial intravitreal methotrexate injection, the
yellowish lesions have changed to retinal pigment epithelial atrophy
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There was no significant difference in the mean age
and refractive error between the patients and controls
(P = 0.8958, P = 0.9652, respectively). The interstitial
area and choroidal thickness were significantly increased in
the 5 eyes with pretreatment PIOL (0.1240 ± 0.0200 mm2,
215.6 ± 38.1 μm, respectively) compared with the normal
control eyes (0.1006 ± 0.0157 mm2, P = 0.0207; 174.4 ±
45.1 μm, P = 0.0495; respectively), while the luminal area
was not significantly different (P = 0.2752).
Discussion
The present study showed that eyes with PIOL had a
markedly increased interstitial area of the choroid com-
pared with healthy fellow eyes. In addition, the interstitial
Fig. 2 Enhanced depth imaging optical coherence tomographic (EDI-OCT) images and converted binary images in case 4. Upper row shows EDI-
OCT images before treatment, and lower row shows images 6 months after the initial intravitreal methotrexate injection. EDI-OCT images through
the fovea (a, d) were converted to binary images using ImageJ software. a, d The luminal area (dark area, asterisks) and the interstitial area (light
area, daggers) can be seen. The examined area was determined to be 1,500 μm wide in the subfoveal choroid. It extended vertically from the retinal
pigment epithelium to the chorioscleral border, and the choroidal area was set with the ROI manager of ImageJ. The rectangle surrounded by a red
line was excised, and the dark areas were traced by the Niblack method. b, e Merged images of the binarized images and the margins of traced areas.
In the binarized images, the light pixels were defined as the interstitial choroid or choroidal stroma, and the dark pixels were defined as the luminal
area. c, f Merged images of the original EDI-OCT images and the margins of traced areas show that the traced areas coincide with the dark choroidal
areas of the EDI-OCT image
Table 2 Subfoveal choroidal area and thickness in EDI-OCT images before and after IVMTX
Case No. Side Status Time of examination Interstitial area (mm2) Luminal area (mm2) Choroidal thickness (μm)
1 OD PIOL(+) Pre-IVMTX 0.1371734 0.2060821 224.0
Post-IVMTX 0.1264265 0.2448991 211.5
OS PIOL(+) Pre-IVMTX 0.1364545 0.2145141 220.5
Post-IVMTX 0.1207003 0.2155650 204.0
2 OD PIOL(+) Pre-IVMTX 0.0903745 0.1277632 150.0
Post-IVMTX 0.0849373 0.1390663 118.0
OS History of PIOL 0.9527313 0.1195278 158.0
3 OD Normal 0.1061557 0.3154791 264.0
OS PIOL(+) Pre-IVMTX 0.1353078 0.2085307 238.0
Post-IVMTX 0.1120500 0.1980837 207.5
4 OD Normal→ PIOL(+) Pre-PIOL 0.0741932 0.2257468 184.0
Post-PIOL 0.1089445 0.2276595 212.5
OS PIOL(+) Pre-IVMTX 0.1204610 0.2466626 245.5
Post-IVMTX 0.0997601 0.1735233 172.5
EDI-OCT enhanced depth imaging optical coherence tomography, IVMTX intravitreal injection of methtorexate, OD right eye, OS left eye, PIOL primary intraocular
lymphoma, Pre-PIOL before development of primary intraocular lymphoma, Post-PIOL after development of primary intraocular lymphoma
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area in the affected eye was not increased compared with
the fellow eye with a history of PIOL. Consistent with our
findings, the results of gross examination of the enucle-
ated eye with PIOL showed a thickened choroid as well as
multiple white areas of retinal and subretinal tumor infil-
tration [16]. The present study also showed that choroidal
thickness and the interstitial area were significantly de-
creased after treatment for PIOL. After delayed onset of
PIOL, increased interstitial area, thickened choroid and
unchanged luminal area were observed in one eye. The
interstitial area and choroidal thickness were significantly
increased in the eyes with pretreatment PIOL compared
with the normal control eyes. Choroidal thickness and
interstitial area on EDI-OCT images may have corre-
sponded with an increase in disease activity. Thus, there is
a possibility that EDI-OCT is useful for monitoring the
progression or regression of PIOLs, which may then influ-
ence the management of PIOL cases.
The mechanism of the increased interstitial area of the
choroid in PIOL remains unknown. However, histopatho-
logical studies indicated that accumulation of reactive in-
flammatory cells in the choroid may contribute to the
increased choroidal interstitial area [1, 17, 18]. Reactive in-
flammatory cells are commonly mixed with malignant
lymphoma cells in eyes with PIOL [17]. Lopez et al. [18]
reported an immunohistochemical examination of enucle-
ated globes with PIOL. They found malignant B cells in
the retina, whereas reactive T-cells were concentrated in
the choroid and maintained a CD4/CD8 ratio of 2:1,
which is typical of reactive T cell processes. Read et al.
[17] reported results of a chorioretinal biopsy from a
54-year-old woman with PIOL who lost vision in her
left eye. Pleomorphic, malignant lymphocytes and nec-
rotic debris were detected in the subretinal space, and
the choroid was infiltrated with reactive inflammatory
cells. Chan et al. [1] reported results of immunohisto-
chemistry for enucleated eyes with PIOL, showing an
intense expression of chemokine receptors, CXCR4 and
CXCR5, with malignant lymphoma in the retinal and
subretinal areas, but without lymphocytes infiltrating
the choroid. The presence of T-cells in the choroid was
postulated to reflect an immune response against the
tumor, preventing it from penetrating Bruch’s mem-
brane and extending into the choroid [17, 18].
Another possible mechanism explaining the increased
interstitial area is direct invasion of lymphoma cells into
the choroid. Chan et al. [19] reported a murine model of
PIOL, where lymphoma cells were inoculated into the
vitreous of adult immunocompetent mice, then the eyes
were harvested. In the early period after inoculation,
tumor cells from the vitreous migrated through the ret-
ina and accumulated between the RPE and sensory ret-
ina. More than 2 months after inoculation, lymphoma
cells rarely broke through the RPE and infiltrated the
choroid and sclera. Jang et al. [4] reported longitudinal
SD-OCT changes in eyes with PIOL. In their study,
hyperreflective signals appearing as nodules or bands
were found across the retina, RPE, and/or choroid. In
one of five patients with PIOL, hyperreflective foci were
found in the choroid as well as retina. Thus, direct inva-
sion of lymphoma cells into the choroid may rarely con-
tribute to the increased choroidal interstitial area.
The decrease in choroidal thickness and interstitial area
after treatment for PIOL may be due to a decrease in re-
active inflammatory cells. However, cell toxicity of intravi-
treally injected methotrexate may also contribute to the
decrease in choroidal thickness and interstitial area.
SD-OCT and fundus autofluorescence (FAF) findings
in eyes with PIOL were recently reported, and these im-
aging techniques were shown to be useful for diagnosing
and determining the activity of PIOL. Casady et al. [7]
reported that the nodular hyperreflective spots in the
OCT images were present at the level of the RPE in 6 of
14 eyes (43 %) with PIOL. Jang et al. [4] reported that
the hyperreflective signals were seen as dots, nodules, or
bands throughout the retina and RPE in eyes with PIOL.
In their study, the number of hyperreflective foci in the
inner retina increased with increased activity of PIOL.
Casady et al. [7] showed that the hyperautofluores-
cence spots on FAF images changed to hypoautofluores-
cent spots corresponding to the atrophic areas in the
RPE after treatment for PIOL. Similarly, we have re-
ported that the FAF images had a granular pattern of
slight hypoautofluorescence and hyperautofluorescence
before treatment and patchy hypoautofluorescence cor-
responding to RPE atrophy after the treatments [12].
These differences in the FAF findings may be useful for
determining the sites of PIOL activity.
This study has limitations. We studied only five eyes
with PIOL, and further studies examining a larger num-
ber of cases treated for PIOL will be needed to accur-
ately determine choroidal changes after treatment. In
addition, further studies examining whether choroidal
interstitial area increased with increased PIOL activity
will be necessary.
Conclusions
EDI-OCT and binarization of the EDI-OCT images may
be a useful and noninvasive method to evaluate the
choroid before and after treatment for PIOL. After treat-
ment for PIOL, the EDI-OCT images showed a thinner
choroid and binarization of the EDI-OCT images showed
markedly decreased interstitial areas compared with the
luminal areas. After delayed onset of PIOL, increased
interstitial area, thickened choroid and unchanged luminal
area were observed in one eye. In addition, the interstitial
area was higher before treatment in the affected eye com-
pared with the healthy fellow eye. The interstitial area and
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choroidal thickness were significantly increased in the eyes
with pretreatment PIOL compared with the normal con-
trol eyes, while the luminal area was not significantly dif-
ferent. The binarized EDI-OCT images can provide useful
information on choroidal structure in eyes with PIOL, and
combining these images with intraocular IL levels or FAF
images should provide valuable information for determin-
ing the PIOL activity, which may influence treatment de-
cisions for managing the disease.
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